TransCode Therapeutics (RNAZ) Stock Price, News & Analysis

Company Overview

TransCode Therapeutics, Inc. is a clinical‐stage biotechnology company focused on the development of nonviral, receptor‐targeted nanocomplexes for gene therapy applications. The company’s proprietary platform is designed to deliver nucleic acid payloads—including plasmid DNA, messenger RNA (mRNA) and gene editing tools—to specific cell types by exploiting naturally occurring cell‐surface receptors. This approach aims to enhance both the precision and efficacy of genetic medicines while avoiding some of the safety limitations associated with viral vectors.

The company’s technology leverages modular nanoparticle formulations that can be tailored to target different tissues and disease indications. By combining targeting ligands with biodegradable polymer backbones, TransCode’s nanocomplexes are engineered to achieve receptor‐mediated uptake and endosomal escape, facilitating the intracellular delivery of therapeutic payloads. This receptor‐targeted strategy underpins preclinical programs across areas such as rare genetic disorders, oncology and metabolic diseases.

TransCode’s pipeline includes multiple preclinical and early clinical candidates aimed at underserved patient populations. Collaborations with academic institutions and industry partners support the advancement of these programs, as the company seeks to validate its platform in both in vitro and in vivo models. Its lead candidates are being evaluated for their potential to restore or modulate gene expression in specific cell types, with an eye toward chronic, systemic and localized treatment approaches.

Headquartered in the United States, TransCode Therapeutics operates research and development facilities dedicated to nanoparticle manufacturing and characterization. The company is led by a management team with experience in nanomedicine, gene therapy and pharmaceutical development. Through ongoing investment in manufacturing scale‐up and formulation science, TransCode is positioning itself to address key challenges in the delivery of next‐generation genetic therapies.

Key Stats

• Today's Range: $8.78 to $9.44
• 50-Day Range: $6.63 to $10.00
• 52-Week Range: $6.15 to $894.25
• Volume: 32,231 shs
• Average Volume: 104,680 shs
• Market Capitalization: $7.79 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $280.00
• Consensus Rating: Buy

TransCode Therapeutics Stock Analysis - MarketRank™

TransCode Therapeutics scored higher than 55% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

TransCode Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

TransCode Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for TransCode Therapeutics are expected to grow in the coming year, from ($4.76) to ($4.37) per share.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.47% of the float of TransCode Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

TransCode Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in TransCode Therapeutics has recently decreased by 22.93%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TransCode Therapeutics does not currently pay a dividend.

Dividend Growth

TransCode Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.47% of the float of TransCode Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

TransCode Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in TransCode Therapeutics has recently decreased by 22.93%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

TransCode Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for TransCode Therapeutics this week, compared to 1 article on an average week.

Search Interest

4 people have searched for RNAZ on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added TransCode Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, TransCode Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.10% of the stock of TransCode Therapeutics is held by insiders.

RNAZ Stock Analysis - Frequently Asked Questions

How have RNAZ shares performed this year?

TransCode Therapeutics' stock was trading at $94.36 at the beginning of 2025. Since then, RNAZ stock has decreased by 90.1% and is now trading at $9.38.

How were TransCode Therapeutics' earnings last quarter?

TransCode Therapeutics Inc. (NASDAQ:RNAZ) announced its earnings results on Wednesday, May, 21st. The company reported ($0.60) earnings per share for the quarter, topping the consensus estimate of ($2.00) by $1.40.

When did TransCode Therapeutics' stock split?

TransCode Therapeutics's stock reverse split before market open on Tuesday, January 16th 2024.The 1-40 reverse split was announced on Tuesday, January 16th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did TransCode Therapeutics IPO?

TransCode Therapeutics (RNAZ) raised $25 million in an initial public offering on Friday, July 9th 2021. The company issued 6,250,000 shares at a price of $4.00 per share.

How do I buy shares of TransCode Therapeutics?

Shares of RNAZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of TransCode Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that TransCode Therapeutics investors own include Mullen Automotive (MULN), Plug Power (PLUG), AMC Entertainment (AMC), Nuwellis (NUWE), ARMOUR Residential REIT (ARR), BIOLASE (BIOL) and Imperial Petroleum (IMPP).

Company Calendar

• Last Earnings: 5/21/2025
• Today: 7/16/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RNAZ
• CIK: 1829635
• Web: www.transcodetherapeutics.com
• Phone: 857-837-3099
• Fax: N/A
• Employees: 9
• Year Founded: N/A

Price Target and Rating

• Average Price Target for TransCode Therapeutics: $280.00
• High Price Target: $280.00
• Low Price Target: $280.00
• Potential Upside/Downside: +2,970.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$16.75 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -578.88%
• Return on Assets: -222.61%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.20
• Quick Ratio: 5.20

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($54.96) per share
• Price / Book: -0.17

Miscellaneous

• Outstanding Shares: 830,000
• Free Float: 832,000
• Market Cap: $7.57 million
• Optionable: Not Optionable
• Beta: 1.40